The present experiment aims to evaluate tumor suppressive effects of a selective inhibitor of cyclooxygenase-2 (CoX-2) celecoxib (Celebrex, pfizer) administered alone and in combination with melatonin in the prevention of N-methyl-Nnitrosourea (NmU)-induced mammary carcinogenesis in sprague-dawley female rats. Celecoxib was administered daily at a concentration of 1.666 g/kg diet to two groups during 20 weeks (starting a week before first NmU application). a combination of celecoxib and melatonin applied in drinking water (20 µg/ml drinking water), daily from 15:00 to 08:00 hours was administered to the second group. The anticarcinogenic effects of chemopreventive drugs were compared with control (NmU) animals. Celecoxib administration decreased mammary tumor incidence (by 24%), while combination of celecoxib and melatonin decreased tumor incidence even more significantly (-30%). significant decrease in tumor frequency per group was recorded in both groups with chemoprevention: celecoxib alone (-54%) and combination of celecoxib and melatonin (-64%). Celecoxib significantly influenced tumor frequency per animal in the group with combination of both protective substances (-52%). Celecoxib administration resulted in prolonged latency by 3%, and by 13% in the group with combination of both protective substances. These results confirm preventive effects of celecoxib in induced rat mammary carcinogenesis. The administration of isolated mel had only lesser effect, but in the combination with Cele revealed some potentiating influence in mammary carcinogenesis inhibition.
* Corresponding author mammary gland cancer presents a serious health issue worldwide. It is one of the most frequent malignancies in women in industrialised countries and it is the second most frequent cause of death in women with cancer. annually, breast cancer is diagnosed in 40 000 women only in the UK [1] .
apart from maintaining a healthy lifestyle, chemoprevention is efficient to combat mammary gland can cer. Non-ste roi dal antiinflammatory drugs (NsaIds) have been found to have chemopreventive effects. NsaIds be long to the most fre quently used drugs worldwide; with as many as 20 to 30 % of the population in the developed coun tries taking pre scribed forms of these agents [2] . NsaIds are of ten used in the treatment of rheumatic dis eases, to alle viate pain and functional im pairment.
several retrospective clinical studies aimed at a long-term application of various NsaIds reported significant decrease in the incidence of colon cancer [3] , mammary gland cancer [4] , prostate [5] and lung cancer [6] . The studies with laboratory animals proved chemopreventive effect of NsaIds in various types of neoplasia, including mammary gland can cer. dietary ibuprofen and celecoxib administration (one week before carcinogen application to the end of the experiment -105 days after the application of 7,12-dimethylbenzanthracene -dmBa) in mammary tumorigenesis decreased tumor in ci dence, tumor frequency and tumor volume in female rats; celecoxib proved to be more efficient [7] . Nimesulide applied in a high-fat diet in rat mammary carcinogenesis induced by 2-amino-1-methyl-6-fenylimidazol (4,5-b) pyridine reduced tumor incidence, frequency and volume as opposed to the group without nimesulide [8] . 
CELECOXIB AND MELATONIN IN PREVENTION OF CARCINOGENESIS
Our group proved chemopreventive effects of indomethacin administered in drinking water [9] , diclofenac administered in drinking water [10] , nimesulide applied subcutaneously [11] and rofecoxib applied in a laboratory diet [12] in mammary carcinogenesis in female Sprague-Dawley rats. Certain anticarcinogenic effect of etoricoxib administered in a laboratory diet [13] was recorded in female Sprague-Dawley rats.
From the pharmacodynamic point of view, COX-1 inhibitors (acetylsalicylic acid, indomethacin, ibuprofen) display serious side effects on the gastrointestinal tract associated with their long-term application. These undesirable effects are markedly reduced in administration of COX-2 inhibitors. Several recent studies pointed to an increased incidence of thromboembolic complications associated with the use of coxibs [14, 15] . Increased incidence for vascular events was reported also for long-term administration of ibuprofen and diclofenac; rofecoxib and celecoxib were associated with increased risk of myocardial infarction attributable to higher daily dose intake [15] . Discussion on possible risks of coxibs resulted in withdrawal of certain pharmaceuticals from the market in 2004. Since then the use of coxibs has gone hand in hand with criticism, fear, and skepticism. Disputes have been going on and no agreement has been reached regarding the issue of "identical" or "different" effect of NSAIDs and coxibs on cardiovascular system [16] . Targeted prospective studies with the above cited drugs may find the answers to the discussed issues.
Celecoxib belongs to the NSAIDs, which selectively inhibit COX-2. The drug (Celebrex, Pfizer) was the first specific COX-2 inhibitor used in clinical practice. It was approved by Food and Drug Administration (FDA) in the USA in 1988 for use in rheumatoid arthritis, ostheoarthritis and familial adenomatous polyposis treatment. In 2001 it was indicated to treat acute pain conditions and primary dysmenorrhoea, too.
Melatonin (5-methoxy-N-acetyltryptamine) is a pineal gland hormone, produced also in the retina and gastrointestinal tract. Antitumour effect of melatonin was observed mainly in estrogen-sensitive tumors (mammary gland and prostate tumors), but also in cervical tumors, Lewis lung carcinoma, hepatocarcinoma, melanoma and ovarian carcinoma [17, 18] . Numerous experimental studies pointed to tumor suppressive effects of melatonin via several mechanisms. Blask et al. [18] emphasised possible anti-estrogenic effect of melatonin in NMU-induced rat mammary carcinogenesis. Blask and Hill [19] points to a possible tumor suppressive effect of melatonin by inhibition of linoleic acid and its metabolite 13-hydroxyoctadecadienoic acid utilisation. Besides the antioxidative properties with free radical scavenging, MEL displays some immunomodulatory and especially antiinflammatory activities. MEL stimulates the production of IL-2, IL-6, IL-12 and depresses the effectiveness of other cytokines (interleukin-8, tumor necrosis factor-α) /review [20] /.
The present study investigates anticarcinogenic effect of celecoxib in NMU-induced mammary carcinogenesis administered alone or in combination with melatonin.
Materials and methods
Female Sprague-Dawley rats (AnLab, Prague, Czech Republic) aged 30-35 days, weighing 101-125 g were used in the experiment. The animals were adapted to standard vivarium conditions with the temperature 23±2 °C, relative humidity 60-70%, artificial regimen light : dark = 12:12 h, with lights on from 7.00 h (light intensity 150 lux per cage, light source: fluorescent lamps Tesla -40W). During the experiment the animals drank tap water ad libitum. Mammary carcinogenesis was induced by N-methyl-N-nitrosourea (NMU) (Sigma, Deisenhofen, Germany), administered intraperitoneally in two doses, each per 50mg/kg b.w., with a six-day interval between 42 nd -48 th postnatal days. NMU was freshly prepared by dissolving in isotonic saline solution (0.5 ml per animal). Celecoxib (Celebrex, Pfizer Pharmaceuticals Group, New York, USA) was applied in the Ssniff diet (Soest, Germany), at a concentration of 1.666 g/kg food (CELE 0,1666%). Melatonin (Sigma, Deisenhofen, Germany) was applied 3 days before carcinogen administration in drinking water at a concentration of 20 μg/ml daily from 15.00 to 8.00 (from 8.00 to 15.00 animals drank tap water). Melatonin solution was freshly prepared three times a week. Twenty mg of melatonin were diluted in 0.4 ml of 30 % ethanol and mixed up with tap water to the desired volume. Chemoprevention with celecoxib began 7 days before carcinogen administration and lasted until the end of the experiment (20 weeks after NMU administration). The animals were divided into five groups: 1. control group, intact, without chemoprevention and carcinogen, 2. control group without chemoprevention but with carcinogen (NMU), 3. chemoprevention with celecoxib 1.666 g/kg food (CELE 0.1666%), 4. chemoprevention with melatonin (20 μg/ml of drinking water), 5. chemoprevention with celecoxib 1.666 g/kg of food (CELE 0.1666%) and melatonin (20 μg/ml of drinking water). Each group included 20 animals at the beginning of the experiment. The animals were weekly weighed and palpated in order to record the incidence, number, location and size of tumors. In the 20 th week of the experiment (dated from the first NMU application), the animals were sacrificed by quick decapitation. Mammary tumors were excised, weighed, tumor size was recorded and histological typing was performed. The following basic parameters of mammary carcinogenesis were assessed in each group: 1. tumor incidence as the percentage of tumor-bearing animals in a group, 2. tumor frequency per group as the average number of tumors per group, 3. tumor frequency per animal as the average number of tumors per tumor-bearing animals, 4. average tumor volume, 5. latency period determined by the period between carcinogen administration to the appearance of the first tumor. The effect of a chemopreventive agent on the body mass gain (evaluated from the initiation until the end of the experiment), food and water intake was observed. Food and water intake during 24 h was recorded in the 5 th , 12 th and 19 th week after carcinogen administration in 6 measurements (twice in a given week).
Tumor incidence was evaluated by Mann-Whitney U-test, other parameters by one-way analysis of variance or Kruskal- 
Results
Preventive effect of celecoxib, melatonin and their combination in female Sprague-Dawley rat mammary carcinogenesis is summarised in Tab.1. A pronounced tumor suppressive effect of celecoxib applied alone was observed in tumor incidence, tumor frequency per group and animal and prolonged latency. Less marked antineoplastic effect was observed after melatonin alone and this was documented by prolonged latency and decreased tumor frequency per group and animal. More efficient tumor suppressive effect of combination of celecoxib and melatonin was found in tumor frequency per group and animal. Tumor incidence decreased non significantly by 24% in the CELE group and by 25% in the CELE+MEL group as opposed to the NMU control group. Significant decrease in tumor frequency per group by 54% and 64% was recorded in the CELE and CELE+MEL group, respectively, as opposed to the control group (NMU). Significantly decreased tumor frequency per animal by 40% was found in the CELE group and by 52% in the CELE+MEL opposed to the control. Melatonin alone non significantly decreased both parameters -tumor frequency per group and animal by 20% as opposed to the control only with NMU. Latency was prolonged non significantly by 14.8 days (+19%) in the MEL group, by 10.1 days (+13%) in the CELE+MEL group and by 2.3 days (+3%) in the CELE group when compared to the control only with NMU. Increase of average tumor volume in all the groups with chemoprevention was caused by high incidence of new tumors with small volume in the control group NMU. Invasive cribriform carcinomas and ductal in situ carcinomas prevailed in the histological typization among tumors in individual groups. The malignant/benign tumor ratio oscillated between 91% -93% and 7% -9%. /Tab. 2/ 
Total number 100 35 88 23
IC -invasive carcinoma cribriform; IS-C -ductal in situ carcinoma cribriform; IS-P,C -ductal in situ carcinoma papillary and cribriform; PCA -carcinoma papillary; IS-P -ductal in situ carcinoma papillary; IC,CO -invasive carcinoma cribriform with comedo carcinoma; IC-SOL -invasive carcinoma solid; I-CO -invasive carcinoma comedo; T.ACA -tubular adenocarcinoma; CS -carcinosarcoma; IS-C,CO -ductal in situ carcinoma cribriform and comedo; IS-P,C,CO -ductal in situ carcinoma papillary, cribriform, comedo; IS-C,TA -ductal in situ carcinoma cribriform and tubular adenoma; IC,P -invasive carcinoma cribriform and papillary; IS-CO -ductal in situ carcinoma comedo; IC,IS -invasive carcinoma cribriform and ductal in situ carcinoma; IS-P,C,FA -ductal in situ carcinoma papillary, cribriform, fibroadenoma; TAtubular adenoma; FA -fibroadenoma; PAP -papilloma. Dominant type in mixed tumors is the first in order. CELECOXIB AND MELATONIN IN PREVENTION OF CARCINOGENESIS Daily dose of celecoxib in CELE group ranged from 149 μg to 159 μg of celecoxib/g b.w. (resp. 32.4 mg -40.5 mg celecoxib/per animal) and 138 μg -148 μg of celecoxib/g b.w. (resp. 32.4 mg -35.1 mg celecoxib/per animal) in CELE+MEL group. Significant decrease in food intake was observed in the 5 th week of the experiment in the group CELE (-14%) and CELE+MEL (-15%) as opposed to the control group NMU.
Significant decline in food intake was observed in the 12 th week of the experiment in the group CELE+MEL when compared to the group with melatonin alone (-52%). A lower food intake was recorded only in the group with CELE+MEL (-50%) as opposed to NMU group. Changes in food intake were recorded in the 19 th week of the experiment in the group CELE+MEL with a significant decrease when compared to the group with melatonin alone (-55%). Statistically significant decrease in food intake was found in CELE+MEL group (-52%) as opposed to the control only with NMU. /Tab. 4/ Daily water intake per rat in individual groups ranged from 26.48 ml to 37.34 ml in the 5 th week of the experiment, from 21.25 ml to 37.92 ml in the 12 th week, from 21.00 ml to 36.38 ml in the 19 th week of the experiment. A decreased water intake was recorded in the group with celecoxib in the 12 th week of the experiment as opposed to NMU group (-32%). Water intake in NMU was decreased by 18% when compared to intact group.
In the 19 th week of the experiment, a significantly lower water intake was recorded in the group receiving celecoxib alone as opposed to NMU group (-29%). Similar effect of celecoxib on water intake was also observed in the group with combination of celecoxib and melatonin; and it was documented by significant decrease as opposed to NMU group and MEL group (-31%, -41%). /Tab. 4/ Average body weight of rats decreased in NMU group (-15%) when compared to intact group. Significant decrease in average body weight was observed in the groups CELE and CELE+MEL at the end of the experiment consistently by 7% in both groups as opposed to the control group (NMU). /Tab. 3/
Discussion
At present, medical practice prefers NSAIDs with predominant COX-1 inhibition, derivatives of arylalkanoic acids-acetic acid (e.g. diclofenac, indomethacin) and propionic acid (e.g. ibuprofen, naproxen) and oxicams (e.g. piroxicam, meloxicam); with predominant COX-2 inhibition (nimesulide), or selective COX-2 inhibition: coxibs (celecoxib, rofecoxib, valdecoxib, parecoxib, etoricoxib, lumiracoxib).
Coxibs were reported not only to have beneficial effects in locomotory apparatus diseases but also preventive effects in carcinogenesis. Clinical studies with celecoxib prevention in patients suffering from familial adenomatous polyposis reported significant decrease in colon and rectal polyps (by 28%) [21] . One of the most important retrospective studies pointed to a decreased incidence of several malignancies after 5 or more years of ibuprofen and aspirin use (100 mg and more per day), of these: 63% for colorectal cancer, 62% for gastric and 47% for ovarian cancer. Moreover, it suggests that preventive effects of NSAIDs are dose and time dependent [22] . The Harris et al. [23] study was aimed to the comparison of anticarcinogenic efficacy of selective (celecoxib, rofecoxib) COX-2 inhibitors and inhibitors with prevalent COX-1 inhibition (aspirin, ibuprofen, 
Data are expressed as means ±SEM. naproxen) and found reduced risk (-70%) of mammary tumorigenesis in COX-2 inhibitor users. Experimental studies proved chemopreventive effects of NSAIDs in various types of neoplasia, including mammary gland cancer. In McCormick et al. [24] study indomethacin administration to female Sprague-Dawley rats in a dose of 25 or 50 mg/kg diet, respectively during 207 days decreased mammary tumor incidence induced by DMBA. The experiments with indomethacin conducted by our group in DMBAinduced mammary carcinogenesis in female Sprague-Dawley rats reported a decreased mammary tumor incidence by 63%, decreased tumor frequency per group by 88 % and prolonged latency by 59 days as opposed to control group [9] . Chemopreventive effect of diclofenac administered in drinking water to female Sprague-Dawley rats significantly decreased mammary gland tumor incidence, the frequency per group, and tumor volume [10] . Nimesulide administration with a high-fat diet in chemically induced rat mammary carcinogenesis by 2-amino-1-methyl-6-fenylimidazol [4,5-b] pyridine -PhIP reduced incidence, frequency and tumor volume as opposed to the group with high-fat diet without NIM [8] . Tumor suppressive effect of nimesulide (applied subcutaneously twice a week) was found out by our group in NMU-induced mammary carcinogenesis in female SpragueDawley rats [11] . No oncostatic effect of nimesulide was found in the above-mentioned experiment in DMBA-induced mammary carcinogenesis.
Our further studies were focused on preventive effects of coxibs in experimental mammary carcinogenesis. Dietary administered rofecoxib (selective COX-2 inhibitor) in NMUinduced mammary carcinogenesis in female Sprague-Dawley rats markedly decreased tumor incidence and frequency and prolonged latency period by 8 days [12] . The study focused on prevention of NMU-induced mammary carcinogenesis by etoricoxib (selective inhibitor COX-2) administered with diet to female Sprague-Dawley rats reported a tumor suppressive effect at a higher dose (0.025 mg/1 g diet) documented by a slight decrease in tumor incidence, tumor frequency per group, and prolonged latency by 7 days [13] .
Anticarcinogenic effect of celecoxib documented by changes in basic parameters of carcinogenesis was observed in this study. Celecoxib administered alone and in combination with melatonin reduced tumor incidence. Pronounced decrease in tumor incidence was observed by Kubatka et. al. [12] after rofecoxib application. In our experiment, celecoxib markedly decreased tumor frequency per group and animal but increased tumor volume. Similar changes in tumor volume were found after etoricoxib application at a dose of 0.025mg/g diet [13] . As opposed to the effect of celecoxib and etoricoxib, administration of rofecoxib in the study by Kubatka et al. [12] decreased tumor volume. Celecoxib prolonged latency period as opposed to the control group only with NMU, similarly to rofecoxib [12] and etoricoxib [13] . Celecoxib reduced body weight gain per animal when compared to the control group (NMU). This may be attributed to its anorexigenic effect resulting in obvious decrease in food and water intake. These changes may be associated with a relatively high dose of celecoxib similar to that used by Harris et al. [7] . A slight decrease in body weight in the groups with rofecoxib was observed by Kubatka et al. [12] too.
Abou-Issa et al. [25] recorded inhibition of DMBA-induced mammary carcinogenesis in female Sprague-Dawley rats by celecoxib (0.25 g/kg, 0.50 g/kg, 1.00 g/kg or 1.50 g/kg diet) administered in diet. Harris et al. [7] pointed to an obvious antitumor effect of dietary administered celecoxib (1.50 g/kg diet) in DMBA-induced mammary carcinogenesis in female Sprague-Dawley rats.
Anticarcinogenic effect of melatonin (MEL) administered alone or in combination with another chemoprevention was investigated in our previous studies. Continuous administration of melatonin in drinking water at a concentration of 100 μg/ml during 25 weeks (melatonin was administered after DMBA application) reduced mammary tumor frequency per animal [26] . More pronounced anticarcinogenic effect was observed when MEL was administered before carcinogen application. Prolonged latency period was found out by Bojková et al. [27] in NMU-induced carcinogenesis with melatonin applied in drinking water (20 μg/ml). In the experiment carried out by Kubatka et al. [28] melatonin applied in drinking water at a concentration of 4 μg/ml markedly reduced tumor frequency (by 50%) in NMU-induced carcinogenesis. Blask et al. [29] reported decreased tumor incidence, number and size and prolonged latency period in female Sprague-Dawley rats 3 weeks after DMBA-induced carcinogenesis. The animals were administered melatonin at a concentration of 250 mg per animal during 12 weeks. Obvious anticarcinogenic effect of indomethacin and melatonin in DMBA-induced carcinogenesis was recorded in the experiment by Môciková-Kalická et al. [9] ; however, the addition of melatonin did not substantially influenced the anticarcinogenic effect. No additive oncostatic effect of melatonin in combination with nimesulide on female rat mammary carcinogenesis was observed in further experiment [11] . Administration of exogenous MEL influenced the mammary carcinogenesis parameters in female SD rats induced by the chemical carcinogen (NMU) and psychoemotional stress (immobilization) [30] . Recently the inhibition of COX-2 activity by MEL was described [31] . Our data suggest rather insufficient action of isolated MEL, but the combination with a coxib (CELE) displayed an enhanced effect in mammary carcinogenesis inhibition, namely in tumor frequency reduction.
More research should be done to find the proper dose, frequency, and application method of melatonin combined with other chemopreventive substances.
This study confirmed that preventive effects of coxibs including celecoxib in experimental mammary carcinogenesis cannot be overlooked. Removal of side effects of coxibs may offer a new promise for their use in cancer prevention.
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